特拉唑嗪对左氧氟沙星在大鼠细菌性前列腺炎组织和血浆中药物浓度的影响
|
摘要
目的探讨特拉唑嗪对大鼠灌服左氧氟沙星后前列腺炎组织和血浆中药物浓度的影响。
方法建立SD雄性大鼠急性细菌性前列腺炎模型96只,随机分为单服左氧氟沙星组和联合使用特拉唑嗪组,每组48只,分别于给药后0.125、0.25、0.5、1、2、4、8和12 h每个时间点活杀6只大鼠,采集2组动物的血液及前列腺制作组织匀浆,HPLC法测定前列腺组织及血浆的左氧氟沙星浓度,3p97软件计算药动学参数。
结果实验组与对照组动物前列腺组织中的左氧氟沙星浓度有显著性差异,而血浆中左氧氟沙星浓度无显著性差异。
结论特拉唑嗪可提高左氧氟沙星在大鼠前列腺炎组织中的浓度,而对血浆中的浓度无影响。
AIM To investigate the effect of terazosin on the distribution of levofloxacin in the rat’s bacterial prostatitis tissue and plasma.
METHOD 96 male SD rats were used to set up the model of acute bacterial prostatitis.,which were equally randomized into two groups: the only levofloxacin orally administered group and the combined terazosin and levofloxacin administered group. Six rats were sacrificed to collect their plasma and prostates to make tissue homogenate at each time point: 0.125 ,0.25 , 0.5 ,1 ,2 ,4 ,8 ,12 h after drug administration. The prostatic and plasma levofloxacin concentrations were detected by HPLC, and pharmacokinetic parameters were calculated by the 3p97 software program.
RESULT There isn’t significant difference about the concentration of levofloxacin in plasma between experimental group and control group,but there is significant difference in prostate.
CONCLUSION Terazosin can elevate the concentration of levofloxacin in the rat’s prostatitis tissue, but not in the plasma.
方法建立SD雄性大鼠急性细菌性前列腺炎模型96只,随机分为单服左氧氟沙星组和联合使用特拉唑嗪组,每组48只,分别于给药后0.125、0.25、0.5、1、2、4、8和12 h每个时间点活杀6只大鼠,采集2组动物的血液及前列腺制作组织匀浆,HPLC法测定前列腺组织及血浆的左氧氟沙星浓度,3p97软件计算药动学参数。
结果实验组与对照组动物前列腺组织中的左氧氟沙星浓度有显著性差异,而血浆中左氧氟沙星浓度无显著性差异。
结论特拉唑嗪可提高左氧氟沙星在大鼠前列腺炎组织中的浓度,而对血浆中的浓度无影响。
AIM To investigate the effect of terazosin on the distribution of levofloxacin in the rat’s bacterial prostatitis tissue and plasma.
METHOD 96 male SD rats were used to set up the model of acute bacterial prostatitis.,which were equally randomized into two groups: the only levofloxacin orally administered group and the combined terazosin and levofloxacin administered group. Six rats were sacrificed to collect their plasma and prostates to make tissue homogenate at each time point: 0.125 ,0.25 , 0.5 ,1 ,2 ,4 ,8 ,12 h after drug administration. The prostatic and plasma levofloxacin concentrations were detected by HPLC, and pharmacokinetic parameters were calculated by the 3p97 software program.
RESULT There isn’t significant difference about the concentration of levofloxacin in plasma between experimental group and control group,but there is significant difference in prostate.
CONCLUSION Terazosin can elevate the concentration of levofloxacin in the rat’s prostatitis tissue, but not in the plasma.
引文
[1] Krieger JN, Riley DE, Cheah PY, et al. Epidemiology of prostatitis: new evidence for a world-wide problem[J]. World J Urol,2003,2:70-74.
[2] Ku JH, Kim ME, Lee NK, et al. Influence of environmental factors on chronic prostatitis-like symptoms in young men: results of a community-based survey[J]. Urology,2001, 58:853-858.
[3] Tan JK, Png DJ, Liew LC, et al. Prevalence of prostatitis-like symptoms in Singapore: a population-based study[J]. Singapore Medical Journal, 2002, 43:189-193.
[4] Cheah PY, Liong ML, Yuen KH, et al. Chronic prostatitis: symptoms survey with follow-up clinical evaluation[J]. Urology,2003, 61:60-64.
[5] Kunishima Y, Matsukawa M, Takahashi S, et al. National institutes of health chronic prostatitis symptom index for Japanese men[J]. Urology, 2002, 60:74-77.
[6] Roberts RO, Lieber MM, Rhodes T, et al. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men[J]. Urology,1998,51:578-584.
[7] Collins MM, Stafford RS, O’Leary MP, et al. Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: results of a national survey of physician visits[J]. Urology,1999, 53:921-925.
[8] Nickel JC, Downey J, Hunter D, et al. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index[J]. J Urol, 2001, 165:842-845.
[9] Nickel JC, Downey JA, Nickel KR, et al. Prostatitis-like symptoms: one year later[J]. Br J Urol Int,2002, 90:678-681.
[10] Collins MM, Meigs JB, Barry MJ, et al. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort[J]. J Urol,2002, 167:1363-1366.
[11]夏同礼,孔祥田,宓培,等.我国成人前列腺非特异性炎[J].中华泌尿外科杂志,1995,16:711-713.
[12] McMeal JE. Regional morphology and pathology of the prostate[J]. Am J Clin Pathol,1968, 49:347-357.
[13] Calhoun EA, McNaughton Collins M, Pontari MA, et al. The economic impact ofchronic prostatitis[J]. Arch Inter Med. 2004,164:1231-1236.
[14]张杰秀,华立新,钱立新,等.急性前列腺炎综合治疗35例报告[J].中华泌尿外科杂志, 2005, 26(12):855.
[15]王景顺,田浩,朱建周.感染性前列腺炎五年来菌谱及耐药性分析[J].医学信息, 2006,19(2):299-301.
[16] ANDREU A, STAPLETON AE, FENNELL C, et al. Urovirulence determinants in Escherichia coli strains causing prostatitis[J]. J Infect Dis, 1997, 176(2):464-469.
[17] 17. MILLAN-RODRIGUEZ F, PALOU J, BUJONS-TUR A, et al. Acute bacterial prostatitis: two different sub-categories according to a previous manipulation of the lower urinary tract[J]. World J Urol, 2006, 24(1):45-50.
[18] TERAI A, ISHITOYA S, MITSUMORI K, et al. Molecular epidemiological evidence for ascending urethral infection in acute bacterial prostatitis[J]. J Urol, 2000, 164(6):1945-1947.
[19] ROWE E, SMITH C, LAVERICK L,et al. A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup[J]. J Urol, 2005, 173(6):2044-2047.
[20] PONTARI MA, MCNAUGHTON-COLLINS M, O'LEARY MP, et al. The CPCRN Study Group. A case-control study of risk factors in men with chronic pelvic pain syndrome[J]. BJU Int, 2005, 96(4):559-565.
[21]孟安启,郑少斌,陈彤,等.慢性前列腺炎发病的多因素分析[J].第一军医大学学报, 2002 ,22(9):846-848.
[22] SHORTLIFFE LM, SELLERS RG, SCHACHTER J. The characterization of nonbacterial prostatitis: search for an etiology[J]. J Urol, 1992, 148(5):1461-1466.
[23] WAGENLEHNER FM AND NABER KG. Antimicrobial treatment of prostatitis[J]. Expert Rev Anti Infect Ther, 2003, 1(2): 275-282.
[24] Fowler JE Jr. Antimicrobial therapy for bacterial and nonbacterial prostatitis[J]. Urology, 2002,60 (6 Suppl): 24-26.
[25] BUNDRICK W, HERON SP, RAY P, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. J[J].Urology, 2003, 62(3):537-541.
[26] NABER KG; European Lomefloxacin Prostatitis Study Group. Lomefloxacinversus ciprofloxacin in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents[J]. 2002, 20(1):18-27.
[27] MEHIK A, ALAS P, NICKEL JC, et al. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study[J]. Urology, 2003, 62(3): 425-429.
[28] EVLIYAOGLU Y, BURGUT R. Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo[J]. Int Urol Nephrol, 2002, 34(3):351-356.
[29]李昕,李宁忱,丁强,等.α1肾上腺素能受体阻滞剂萘哌地尔治疗慢性非细菌性前列腺炎的临床研究[J].中华男科学杂志, 2006,12(3): 234-236.
[30] NICKEL JC, NARAYAN P, MCKAY J, et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial[J]. J Urol, 2004, 171(4): 1594-1597.
[31] CHEAH PY, LIONG ML, YUEN KH, et al. Terazosin therapy for chronic prostatitis/ chronic pelvic pain syndrome: a randomized, placebo controlled trial[J]. J Urol, 2003, 169(2): 592-596.
[32] Youn CW, Son KC, Choi HS,et al. Comparison of the Efficacy of Antibiotic Monotherapy and Antibiotic Plus Alpha-blocker Combination Therapy for Patients with Inflammatory Chronic Prostatitis/Chronic Pelvic Pain Syndrome[J].Korean Journal of Urology,2008,49(1):72-76.
[33] Kulovac B,Aganovi? D,Prci? A,et al. Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome[J]. Bosnian journal of basic medical sciences,2007,7(3):245-249.
[34] Ye ZQ,Lan RZ,Yang WM,et al. Tamsulosin treatment of chronic non-bacterial prostatitis[J]. The Journal of international medical research,2008,36(2):244-252.
[35]吴金虎,张晓燕,肖雨清,等.大鼠前列腺炎模型的建立[J].山西医药杂志,2006,35(3):193-194.
[36] ELKAHWAJI JE,OTT CJ,JANDA LM,et al. Mouse model for acute bacterial prostatitis in genetically distinct inbred strains[J].Urology,2005,66(4):883-887.
[37]安黎明,江鱼.盐酸坦索罗辛对慢性前列腺炎患者尿流率的影响[J].临床泌尿外科杂志,2001,16(3):142-143.
[38]吴荣佩,郑克立,胡红星,等.α1A受体阻滞药治疗慢性前列腺炎疗效观察[J].临床泌尿外科杂志,2001,16(5):207-208.
[39] Barbalias GA,Nikiforidis G,Liatsikos EN.Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics[J].JUrol,1998,159:883-887.
[40]沈柏华,金晓东,蔡松良,等.α1受体阻滞剂联合抗生素治疗慢性前列腺炎疗效及机制[J].中华男科学,2004,10(7):518-520.
[41] ROMICS I. The role of alpha-adrenoreceptors in the treatment of urological diseases[J].Neurochem Int,2007,51(5):328-331.
[42]杨藻宸.选择性肾上腺素受体阻断药[M]//杨藻宸.医用药理学.北京:人民卫生出版社,2005:178-179.
[1] NICKEL JC. Inflammatory conditions of the male genitourinary tract: proatatitis and related conditions,orchitis,and epididymitis[M]//WEIN AJ. Campbell-Walsh Urology.Philadelphia: Tina Rebane,2007:304-305.
[2] MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006;176: 1012–1016.
[3] Lundgren R, Holmquist B, Hesselvik M, Muntzing J. Treatment of prostatitis in the rat. Prostate 1984; 5: 277–284.
[4] Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS, Ewing LL. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 1992; 43: 557–564.
[5] Keith IM, Jin J, Neal Jr D, Teunissen BD, Moon TD. Cell relationship in a Wistar rat model of spontaneous prostatitis. J Urol 2001; 166: 323–328.
[6] Muntzing J, Sufrin G, Murphy GP. Prostatitis in the rat. Scand J Urol Nephrol 1979; 13: 17–22.
[7] Naslund MJ, Strandberg JD, Coffey DS. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol 1988; 140: 1049–1053.
[8] Penna G, Amuchastegui S, Cossetti C, Aquilano F,Mariani R, Adorini L. Spontaneous and induced autoimmune prostatitis in the non-obese diabetic mouse. J Urol 2006; 175 (Suppl): 35.
[9] Nickel JC, Olson ME, Barabas A, Benediktsson H, Dasgupta MK, Costerton JW. Pathogenesis of chronic bacterial prostatitis in an animal model. Br J Urol 1990; 66: 47–54.
[10] Jantos CA, Augustin J, Durchfeld-Meyer B, Baumgartner W, Schiefer HG. Experimental genital tract infection with Chlamydia psittaci (GPIC agent) in male rats. Infection 1998; 26:126–130.
[11] Seo SI, Lee SJ, Kim JC, Choi YJ, Kim SW, Hwang TK et al. Effects of androgen deprivation on chronic bacterial prostatitis in a rat model. Int J Urol 2003; 10: 485–491.
[12]吴金虎,张晓燕,肖雨清,等.大鼠前列腺炎模型的建立[J].山西医药杂志,2006,35(3):193-194.
[13]李孟,刘修恒,黄耿,等.大鼠慢性细菌性前列腺炎模型的建立[J].中华男科学杂志,2007,13(6):557-558.
[14] ELkahwaji JE,Ott CJ,Janda LM,et al.Mouse model for acute bacterial prostatitis in genetically distinct inbred strains [J].Urology,2005,66(4):883-887.
[15] Elkahwaji E, Zhong W, Janda LM, Bjorling DE, Bushman W.Chronic prostatic infection and inflammation induce reactive dysplasia and neoplasia in mice. JUrol 2006; 175 (Suppl): 258
[16] Pacheco-Rupil B, Depiante-Depaoli M, Romero RM, Yantorno C. Experimental autoimmune damage to rat male accessory glands (MAG). Am J Reprod Immunol 1981; 1: 255–261.
[17] Galmarini M, Ferro ME, Riera CM. Delayed hypersensitivity and lesions following isoimmunization with modified rat male accessory glands: kinetics of induction. J Reprod Immunol 1988;13: 147–157.
[18] Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997; 159: 3113–3117.
[19] GilardoniMB, Rabinovich GA, OviedoM, Depiante-DepaoliM. Prostate cancer induction in autoimmune rats and modulation of T cell apoptosis. J Exp Clin Cancer Res 1999; 18: 493–504.
[20] Keetch DW, Humphrey P, Ratliff TL. Development of a mouse model for nonbacterial prostatitis. JUrol 1994; 152: 247–250.
[21] Rivero VE, Cailleau C, Depiante-Depaoli M, Riera CM,Carnaud C. Non-obese diabetic (NOD) mice are genetically susceptible to experimental autoimmune prostatitis (EAP).J Autoimmun 1998; 11: 603–610.
[22]叶伟成,薛慈民,徐兆东,等.免疫佐剂法制作慢性非细菌性前列腺炎小鼠模型的方法[ J ].中华男科学杂志,2001,15(1):29-32.
[23]周晓辉,韩蕾,周智恒,等.免疫性慢性非细菌前列腺炎大鼠模型的形态学与分子生物学特性[J].中华男科学杂志,2005,11(4):290-295.
[24] Naslund MJ, Coffey DS. The differential effects of neonatal androgen, estrogen and progesterone on adult rat prostate growth. JUrol 1986; 136: 1136–1140.
[25] Naslund MJ, Strandberg JD, Coffey DS. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. JUrol 1988; 140: 1049–1053.
[26] Harris MT,Feldberg RS,Lan KM,et al.Expression of proin-flammatory genes during estrogen-induced inflammation of the rat prostate[J].Prostate,2000,44(1):19-25.
[27] Wilson MJ, Woodson M, Wiehr C, Reddy A, Sinha AA. Matrix metalloproteinases in the pathogenesis of estradiol-induced nonbacterial prostatitis in the lateral prostate lobe of the Wistar rat. Exp Mol Pathol 2004; 77: 7–17.
[28] Robinette CL. Sex-hormone-induced inflammation and fibro-muscular proliferation in the rat lateral prostate. Prostate 1988;12: 271–286.
[29] Montironi R, Pomante R, Diamanti L, Magi-Galluzzi C.Apoptosis in prostatic adenocarcinoma following complete androgen ablation. Urol Int 1998; 60 (Suppl 1): 25–29.
[30] Gatenbeck L, Aronsson A, Dahlgren S, Johansson B, Stromberg L. Stress stimuli-induced histopathological changes in the prostate: an experimental study in the rat. Prostate 1987; 11:69–76.
[31] Lang MD, Nickel JC, Olson ME, Howard SR, Ceri H. Rat model of experimentally induced abacterial prostatitis. Prostate 2000;45: 201–206.
[32] Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS, Ewing LL. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 1992; 43: 557–564.
[33] Kwon SM, Kim SI, Chun DC, Cho NH, Chung BC, Park BW et al. Development of rat prostatitis model by oral administra-tion of isoflavone and its characteristics. Yonsei Med J 2001; 42:395–404.
[34] Takechi S, Yokoyama M, Tanji N, Nishio S, Araki N. Nonbacterial prostatitis caused by partial urethral obstruction in the rat. Urol Res 1999; 27: 346–350.
[2] Ku JH, Kim ME, Lee NK, et al. Influence of environmental factors on chronic prostatitis-like symptoms in young men: results of a community-based survey[J]. Urology,2001, 58:853-858.
[3] Tan JK, Png DJ, Liew LC, et al. Prevalence of prostatitis-like symptoms in Singapore: a population-based study[J]. Singapore Medical Journal, 2002, 43:189-193.
[4] Cheah PY, Liong ML, Yuen KH, et al. Chronic prostatitis: symptoms survey with follow-up clinical evaluation[J]. Urology,2003, 61:60-64.
[5] Kunishima Y, Matsukawa M, Takahashi S, et al. National institutes of health chronic prostatitis symptom index for Japanese men[J]. Urology, 2002, 60:74-77.
[6] Roberts RO, Lieber MM, Rhodes T, et al. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men[J]. Urology,1998,51:578-584.
[7] Collins MM, Stafford RS, O’Leary MP, et al. Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: results of a national survey of physician visits[J]. Urology,1999, 53:921-925.
[8] Nickel JC, Downey J, Hunter D, et al. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index[J]. J Urol, 2001, 165:842-845.
[9] Nickel JC, Downey JA, Nickel KR, et al. Prostatitis-like symptoms: one year later[J]. Br J Urol Int,2002, 90:678-681.
[10] Collins MM, Meigs JB, Barry MJ, et al. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort[J]. J Urol,2002, 167:1363-1366.
[11]夏同礼,孔祥田,宓培,等.我国成人前列腺非特异性炎[J].中华泌尿外科杂志,1995,16:711-713.
[12] McMeal JE. Regional morphology and pathology of the prostate[J]. Am J Clin Pathol,1968, 49:347-357.
[13] Calhoun EA, McNaughton Collins M, Pontari MA, et al. The economic impact ofchronic prostatitis[J]. Arch Inter Med. 2004,164:1231-1236.
[14]张杰秀,华立新,钱立新,等.急性前列腺炎综合治疗35例报告[J].中华泌尿外科杂志, 2005, 26(12):855.
[15]王景顺,田浩,朱建周.感染性前列腺炎五年来菌谱及耐药性分析[J].医学信息, 2006,19(2):299-301.
[16] ANDREU A, STAPLETON AE, FENNELL C, et al. Urovirulence determinants in Escherichia coli strains causing prostatitis[J]. J Infect Dis, 1997, 176(2):464-469.
[17] 17. MILLAN-RODRIGUEZ F, PALOU J, BUJONS-TUR A, et al. Acute bacterial prostatitis: two different sub-categories according to a previous manipulation of the lower urinary tract[J]. World J Urol, 2006, 24(1):45-50.
[18] TERAI A, ISHITOYA S, MITSUMORI K, et al. Molecular epidemiological evidence for ascending urethral infection in acute bacterial prostatitis[J]. J Urol, 2000, 164(6):1945-1947.
[19] ROWE E, SMITH C, LAVERICK L,et al. A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup[J]. J Urol, 2005, 173(6):2044-2047.
[20] PONTARI MA, MCNAUGHTON-COLLINS M, O'LEARY MP, et al. The CPCRN Study Group. A case-control study of risk factors in men with chronic pelvic pain syndrome[J]. BJU Int, 2005, 96(4):559-565.
[21]孟安启,郑少斌,陈彤,等.慢性前列腺炎发病的多因素分析[J].第一军医大学学报, 2002 ,22(9):846-848.
[22] SHORTLIFFE LM, SELLERS RG, SCHACHTER J. The characterization of nonbacterial prostatitis: search for an etiology[J]. J Urol, 1992, 148(5):1461-1466.
[23] WAGENLEHNER FM AND NABER KG. Antimicrobial treatment of prostatitis[J]. Expert Rev Anti Infect Ther, 2003, 1(2): 275-282.
[24] Fowler JE Jr. Antimicrobial therapy for bacterial and nonbacterial prostatitis[J]. Urology, 2002,60 (6 Suppl): 24-26.
[25] BUNDRICK W, HERON SP, RAY P, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. J[J].Urology, 2003, 62(3):537-541.
[26] NABER KG; European Lomefloxacin Prostatitis Study Group. Lomefloxacinversus ciprofloxacin in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents[J]. 2002, 20(1):18-27.
[27] MEHIK A, ALAS P, NICKEL JC, et al. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study[J]. Urology, 2003, 62(3): 425-429.
[28] EVLIYAOGLU Y, BURGUT R. Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo[J]. Int Urol Nephrol, 2002, 34(3):351-356.
[29]李昕,李宁忱,丁强,等.α1肾上腺素能受体阻滞剂萘哌地尔治疗慢性非细菌性前列腺炎的临床研究[J].中华男科学杂志, 2006,12(3): 234-236.
[30] NICKEL JC, NARAYAN P, MCKAY J, et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial[J]. J Urol, 2004, 171(4): 1594-1597.
[31] CHEAH PY, LIONG ML, YUEN KH, et al. Terazosin therapy for chronic prostatitis/ chronic pelvic pain syndrome: a randomized, placebo controlled trial[J]. J Urol, 2003, 169(2): 592-596.
[32] Youn CW, Son KC, Choi HS,et al. Comparison of the Efficacy of Antibiotic Monotherapy and Antibiotic Plus Alpha-blocker Combination Therapy for Patients with Inflammatory Chronic Prostatitis/Chronic Pelvic Pain Syndrome[J].Korean Journal of Urology,2008,49(1):72-76.
[33] Kulovac B,Aganovi? D,Prci? A,et al. Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome[J]. Bosnian journal of basic medical sciences,2007,7(3):245-249.
[34] Ye ZQ,Lan RZ,Yang WM,et al. Tamsulosin treatment of chronic non-bacterial prostatitis[J]. The Journal of international medical research,2008,36(2):244-252.
[35]吴金虎,张晓燕,肖雨清,等.大鼠前列腺炎模型的建立[J].山西医药杂志,2006,35(3):193-194.
[36] ELKAHWAJI JE,OTT CJ,JANDA LM,et al. Mouse model for acute bacterial prostatitis in genetically distinct inbred strains[J].Urology,2005,66(4):883-887.
[37]安黎明,江鱼.盐酸坦索罗辛对慢性前列腺炎患者尿流率的影响[J].临床泌尿外科杂志,2001,16(3):142-143.
[38]吴荣佩,郑克立,胡红星,等.α1A受体阻滞药治疗慢性前列腺炎疗效观察[J].临床泌尿外科杂志,2001,16(5):207-208.
[39] Barbalias GA,Nikiforidis G,Liatsikos EN.Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics[J].JUrol,1998,159:883-887.
[40]沈柏华,金晓东,蔡松良,等.α1受体阻滞剂联合抗生素治疗慢性前列腺炎疗效及机制[J].中华男科学,2004,10(7):518-520.
[41] ROMICS I. The role of alpha-adrenoreceptors in the treatment of urological diseases[J].Neurochem Int,2007,51(5):328-331.
[42]杨藻宸.选择性肾上腺素受体阻断药[M]//杨藻宸.医用药理学.北京:人民卫生出版社,2005:178-179.
[1] NICKEL JC. Inflammatory conditions of the male genitourinary tract: proatatitis and related conditions,orchitis,and epididymitis[M]//WEIN AJ. Campbell-Walsh Urology.Philadelphia: Tina Rebane,2007:304-305.
[2] MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006;176: 1012–1016.
[3] Lundgren R, Holmquist B, Hesselvik M, Muntzing J. Treatment of prostatitis in the rat. Prostate 1984; 5: 277–284.
[4] Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS, Ewing LL. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 1992; 43: 557–564.
[5] Keith IM, Jin J, Neal Jr D, Teunissen BD, Moon TD. Cell relationship in a Wistar rat model of spontaneous prostatitis. J Urol 2001; 166: 323–328.
[6] Muntzing J, Sufrin G, Murphy GP. Prostatitis in the rat. Scand J Urol Nephrol 1979; 13: 17–22.
[7] Naslund MJ, Strandberg JD, Coffey DS. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol 1988; 140: 1049–1053.
[8] Penna G, Amuchastegui S, Cossetti C, Aquilano F,Mariani R, Adorini L. Spontaneous and induced autoimmune prostatitis in the non-obese diabetic mouse. J Urol 2006; 175 (Suppl): 35.
[9] Nickel JC, Olson ME, Barabas A, Benediktsson H, Dasgupta MK, Costerton JW. Pathogenesis of chronic bacterial prostatitis in an animal model. Br J Urol 1990; 66: 47–54.
[10] Jantos CA, Augustin J, Durchfeld-Meyer B, Baumgartner W, Schiefer HG. Experimental genital tract infection with Chlamydia psittaci (GPIC agent) in male rats. Infection 1998; 26:126–130.
[11] Seo SI, Lee SJ, Kim JC, Choi YJ, Kim SW, Hwang TK et al. Effects of androgen deprivation on chronic bacterial prostatitis in a rat model. Int J Urol 2003; 10: 485–491.
[12]吴金虎,张晓燕,肖雨清,等.大鼠前列腺炎模型的建立[J].山西医药杂志,2006,35(3):193-194.
[13]李孟,刘修恒,黄耿,等.大鼠慢性细菌性前列腺炎模型的建立[J].中华男科学杂志,2007,13(6):557-558.
[14] ELkahwaji JE,Ott CJ,Janda LM,et al.Mouse model for acute bacterial prostatitis in genetically distinct inbred strains [J].Urology,2005,66(4):883-887.
[15] Elkahwaji E, Zhong W, Janda LM, Bjorling DE, Bushman W.Chronic prostatic infection and inflammation induce reactive dysplasia and neoplasia in mice. JUrol 2006; 175 (Suppl): 258
[16] Pacheco-Rupil B, Depiante-Depaoli M, Romero RM, Yantorno C. Experimental autoimmune damage to rat male accessory glands (MAG). Am J Reprod Immunol 1981; 1: 255–261.
[17] Galmarini M, Ferro ME, Riera CM. Delayed hypersensitivity and lesions following isoimmunization with modified rat male accessory glands: kinetics of induction. J Reprod Immunol 1988;13: 147–157.
[18] Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997; 159: 3113–3117.
[19] GilardoniMB, Rabinovich GA, OviedoM, Depiante-DepaoliM. Prostate cancer induction in autoimmune rats and modulation of T cell apoptosis. J Exp Clin Cancer Res 1999; 18: 493–504.
[20] Keetch DW, Humphrey P, Ratliff TL. Development of a mouse model for nonbacterial prostatitis. JUrol 1994; 152: 247–250.
[21] Rivero VE, Cailleau C, Depiante-Depaoli M, Riera CM,Carnaud C. Non-obese diabetic (NOD) mice are genetically susceptible to experimental autoimmune prostatitis (EAP).J Autoimmun 1998; 11: 603–610.
[22]叶伟成,薛慈民,徐兆东,等.免疫佐剂法制作慢性非细菌性前列腺炎小鼠模型的方法[ J ].中华男科学杂志,2001,15(1):29-32.
[23]周晓辉,韩蕾,周智恒,等.免疫性慢性非细菌前列腺炎大鼠模型的形态学与分子生物学特性[J].中华男科学杂志,2005,11(4):290-295.
[24] Naslund MJ, Coffey DS. The differential effects of neonatal androgen, estrogen and progesterone on adult rat prostate growth. JUrol 1986; 136: 1136–1140.
[25] Naslund MJ, Strandberg JD, Coffey DS. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. JUrol 1988; 140: 1049–1053.
[26] Harris MT,Feldberg RS,Lan KM,et al.Expression of proin-flammatory genes during estrogen-induced inflammation of the rat prostate[J].Prostate,2000,44(1):19-25.
[27] Wilson MJ, Woodson M, Wiehr C, Reddy A, Sinha AA. Matrix metalloproteinases in the pathogenesis of estradiol-induced nonbacterial prostatitis in the lateral prostate lobe of the Wistar rat. Exp Mol Pathol 2004; 77: 7–17.
[28] Robinette CL. Sex-hormone-induced inflammation and fibro-muscular proliferation in the rat lateral prostate. Prostate 1988;12: 271–286.
[29] Montironi R, Pomante R, Diamanti L, Magi-Galluzzi C.Apoptosis in prostatic adenocarcinoma following complete androgen ablation. Urol Int 1998; 60 (Suppl 1): 25–29.
[30] Gatenbeck L, Aronsson A, Dahlgren S, Johansson B, Stromberg L. Stress stimuli-induced histopathological changes in the prostate: an experimental study in the rat. Prostate 1987; 11:69–76.
[31] Lang MD, Nickel JC, Olson ME, Howard SR, Ceri H. Rat model of experimentally induced abacterial prostatitis. Prostate 2000;45: 201–206.
[32] Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS, Ewing LL. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 1992; 43: 557–564.
[33] Kwon SM, Kim SI, Chun DC, Cho NH, Chung BC, Park BW et al. Development of rat prostatitis model by oral administra-tion of isoflavone and its characteristics. Yonsei Med J 2001; 42:395–404.
[34] Takechi S, Yokoyama M, Tanji N, Nishio S, Araki N. Nonbacterial prostatitis caused by partial urethral obstruction in the rat. Urol Res 1999; 27: 346–350.